Windlas Biotech shareholders and shareholding pattern
NSE: WINDLASBSE: 543329Pharmaceuticals & BiotechnologySmall Cap
Windlas Biotech Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2021 · Issue price ₹460
Last close ₹877.40down ₹5.10 (0.58%)BSE ₹877.15
Share price at the NSE close on 27 Oct 2026. Previous close ₹882.50.
27 Oct: open ₹878.10, high ₹887.40, low ₹872.10
52-week range of traded prices to 27 Oct 2026
₹697.40Low, 16 Mar 2026₹1,181.90High, 7 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,811 Cr1,237th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.26
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 3.12
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.72%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 70,47965.8% delivered
Windlas Biotech's shareholding pattern for Sep 2026, filed on 17 Oct 2026, with every filing from Sep 2021: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Windlas Biotech, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters63.31%
- Foreign institutions2.08%
- Indian institutions7.24%
- Individuals and others27.36%
Shareholding pattern, per cent, from Sep 2022
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.95% | 59.95% | 59.95% | 59.95% | 59.95% | 60.75% | 62.38% | 62.82% | 62.82% | 62.82% | 62.82% | 62.51% | 62.51% | 62.51% | 62.34% | 62.34% | 61.99% | 61.99% | 61.90% | 63.31% | 63.31% | |
| Indian promoters | 59.95% | 59.95% | 59.95% | 59.95% | 59.95% | 60.75% | 62.38% | 62.82% | 62.82% | 62.82% | 62.82% | 62.51% | 62.51% | 62.51% | 62.34% | 62.34% | 61.99% | 61.99% | 61.90% | 63.31% | 63.31% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 40.05% | 40.05% | 40.05% | 40.05% | 40.05% | 39.25% | 37.62% | 37.18% | 37.18% | 37.18% | 37.18% | 37.49% | 37.49% | 37.49% | 37.66% | 37.66% | 38.01% | 38.01% | 38.10% | 36.69% | 36.69% |
| Shares in issue | 2,17,94,375 | 2,17,94,375 | 2,17,94,375 | 2,17,94,375 | 2,17,94,375 | 2,15,08,116 | 2,09,46,340 | 2,07,98,575 | 2,07,98,575 | 2,07,98,575 | 2,07,98,575 | 2,09,00,311 | 2,09,00,311 | 2,09,00,311 | 2,09,59,311 | 2,09,59,311 | 2,10,77,239 | 2,10,77,239 | 2,11,06,229 | 2,06,36,229 | 2,06,36,229 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 1,30,65,352 | 1,30,65,352 | 1,30,65,352 | 1,30,65,352 | 43,59,000 | 43,59,000 | 43,59,000 | 43,59,000 | 43,59,000 | 43,59,000 | 43,59,000 | 43,59,000 | 0 | 0 | 0 | – | – | – | – | – | – |
| Promoters' shares locked in | 1,30,65,352 | 1,30,65,352 | 1,30,65,352 | 1,30,65,352 | 43,59,000 | 43,59,000 | 43,59,000 | 43,59,000 | 43,59,000 | 43,59,000 | 43,59,000 | 43,59,000 | 0 | 0 | 0 | – | – | – | – | – | – |
Filings before Sep 2022 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Windlas Biotech promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is AKW WBL Family Private Trust (through its Trustees Ashok Vimla Trusteeship Services Private Limited), 40.61%. The filing names 18 more members with no shares.Promoter buying and selling
| Holder | ||
|---|---|---|
| AKW WBL Family Private Trust (through its Trustees Ashok Vimla Trusteeship Services Private Limited)Indian companies, trusts and others | 40.61% | 83,81,340 |
| Ashok Kumar WindlassIndividuals and Hindu undivided families | 21.32% | 44,00,000 |
| Vimla WindlasssIndividuals and Hindu undivided families | 1.38% | 2,84,000 |
| Prachi Jain WindlassIndividuals and Hindu undivided families | 0.00% | 3 |
| Payal WindlassIndividuals and Hindu undivided families | 0.00% | 3 |
| Manoj Kumar WindlassIndividuals and Hindu undivided families | 0.00% | 3 |
| Hitesh WindlassIndividuals and Hindu undivided families | 0.00% | 3 |
No promoter shares are reported as pledged.
Largest public holders of Windlas Biotech, filing by filing
Per cent, on the same shares as the split above.
| Holder | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mncl Capital Compounder Fund 2Alternative investment funds | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.04% | 1.18% | 1.70% | 1.70% |
| Ajay Kumar AggarwalResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.03% | 1.03% | 1.30% | 1.30% | 1.30% | 1.21% | 1.21% |
| Perpetuity Health To Wealth (H2w) Rising FundAlternative investment funds | – | – | – | – | – | – | – | – | – | 1.01% | 1.11% | 1.29% | 1.29% | 1.29% | 1.29% | 1.29% | 1.19% | 1.19% | 1.18% | 1.11% | 1.11% |
| Persistence Capital Fund IAlternative investment funds | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.09% | 1.35% | 1.47% | 1.51% | 1.52% | – | – |
| PGIM India Equity Growth Opportunities Fund-Series IAlternative investment funds | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.02% | 1.05% | 1.02% | – | – | – | – |
| Malabar India Fund LimitedInstitutions Foreign Portfolio Investor | 1.81% | 1.84% | 1.84% | 1.64% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Inevsco India Smallcap FundResident individuals, over ₹2 lakh at face value | – | – | 2.08% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Bnp Paribas ArbitrageInstitutions Foreign Portfolio Investor | 1.35% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.